Sensitivity of Berry Genomics' early HCC screen exceeds 90%

Berry Genomics Co. Ltd. (SZSE:000710) said its PreCar next-generation sequencing-based liver cancer risk prediction model detected early hepatocellular carcinoma with >90% sensitivity at 95% specificity in a pilot trial. At 99% specificity, the model detected early HCC with 87% sensitivity.

The company is planning additional studies to optimize the model in a program that will recruit more than 10,000 patients at high risk for liver cancer, including more than 5,000 patients with cirrhosis and more than 5,000 patients with HBV infection...